title: [Long-term outcomes of prostate cancer patients treated with combined brachytherapy and maximal androgen blockade].
abstract: OBJECTIVE
  To explore the prognostic factors of prostate cancer (PCa) patients and evaluate the effect of brachytherapy on survival time.
  
  
  METHODS
  A total of 289 PCa were recruited to collect their clinical and survival data. And their possible prognostic factors were analyzed. A further comparison of 5-year cumulative survival rate was made between the patients treated by maximal androgen blockade (MAB) and those on MAB plus brachytherapy.
  
  
  RESULTS
  Their median survival time was 73 (7-144) months. And the 1, 3 and 5-year survival rates were 93.1%, 81.0% and 60.2% respectively. Univariate analysis indicated that prostate volume, basal level of prostate-specific antigen (PSA), Gleason score, tumor stage, PSA nadir, time PSA decreasing to nadir and brachytherapy were all predictive factors for survival time. And multivariate analysis further demonstrated that Gleason score, tumor stage and PSA nadir were independent prognostic indicators. And the combination therapy based on brachytherapy could significantly increase the 5-year cumulative survival rate than MAB-based monotherapy.
  
  
  CONCLUSIONS
  Gleason score, tumor stage and PSA nadir may predict the prognosis of PCa patients. And brachytherapy significantly improves patient survival.
authors.affiliation: Department of Urology, Affiliated Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China. Email: luoyonganzhen@163.com.
authors.forename: Yong
authors.initials: Y
authors.lastname: Luo
authors.affiliation: Department of Urology, Affiliated Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
authors.forename: Neng-bao
authors.initials: NB
authors.lastname: Wei
authors.affiliation: Department of Urology, Affiliated Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
authors.forename: Jia-hui
authors.initials: JH
authors.lastname: Zhao
authors.affiliation: Department of Urology, Affiliated Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
authors.forename: Xin-hao
authors.initials: XH
authors.lastname: Cui
authors.affiliation: Department of Urology, Affiliated Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
authors.forename: Ming-chuan
authors.initials: MC
authors.lastname: Li
authors.affiliation: Department of Urology, Affiliated Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
authors.forename: Yun-hua
authors.initials: YH
authors.lastname: Lin
authors.affiliation: Department of Urology, Affiliated Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
authors.forename: Zhu
authors.initials: Z
authors.lastname: Hou
authors.affiliation: Department of Urology, Affiliated Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
authors.forename: Yi-li
authors.initials: YL
authors.lastname: Han
authors.affiliation: Department of Urology, Affiliated Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
authors.forename: Yong-guang
authors.initials: YG
authors.lastname: Jiang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D001918:Brachytherapy; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists